Inventor · disambiguated record
Luigi Naldini
Also filed as: NALDINI LUIGI
35 granted patents·21 pending applications·2,514 citations·filing 1995–2025
98Inventor score
Files withOSPEDALE SAN RAFFAELE SRL22CELL GENESYS INC7NALDINI LUIGI4SANGAMO BIOSCIENCES INC3SANGAMO THERAPEUTICS INC3
Top patents by PatentIndex Score
56 records- 0198US6428953B1Method and means for producing high titer, safe, recombinant lentivirus vectorsCELL GENESYS INC·Filed 2000·Granted Aug 6, 2002·125 cites·9 claims
- 0298US6013516AVector and method of use for nucleic acid delivery to non-dividing cellsSALK INST FOR BIOLOGICAL STUDI·Filed 1995·Granted Jan 11, 2000·1.1k cites·6 claims
- 0398US5994136AMethod and means for producing high titer, safe, recombinant lentivirus vectorsCELL GENESYS INC·Filed 1997·Granted Nov 30, 1999·743 cites·16 claims
- 0496US7083981B2Method and means for producing high titer, safe, recombinant lentivirus vectorsCELL GENESYS INC·Filed 2005·Granted Aug 1, 2006·26 cites·14 claims
- 0596US6165782AMethod and means for producing high titer, safe, recombinant lentivirus vectorsCELL GENESYS INC·Filed 1999·Granted Dec 26, 2000·182 cites·9 claims
- 0695US8956828B2Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleasesBONINI MARIA CHIARA·Filed 2010·Granted Feb 17, 2015·203 cites·15 claims
- 0795US8846385B2Method and means for producing high titer, safe recombinant lentivirus vectorsNALDINI LUIGI·Filed 2006·Granted Sep 30, 2014·31 cites·18 claims
- 0894US9937207B2Targeted disruption of T cell receptor genes using talensSANGAMO BIOSCIENCES INC·Filed 2014·Granted Apr 10, 2018·37 cites·13 claims
- 0991US7250299B1Method and means for producing high titer, safe, recombinant lentivirus vectorsCELL GENESYS INC·Filed 2000·Granted Jul 31, 2007·31 cites·18 claims
- 1088US10000757B2Gene vectorNALDINI LUIGI·Filed 2006·Granted Jun 19, 2018·9 cites·12 claims
- 1186US10912824B2Vector productionOSPEDALE SAN RAFFAELE SRL·Filed 2015·Granted Feb 9, 2021·4 cites·24 claims
- 1286US8936936B2Methods and compositions for targeted integrationHOLMES MICHAEL C·Filed 2008·Granted Jan 20, 2015·12 cites·16 claims
- 1386US6924144B2Method and means for producing high titer, safe, recombinant lentivirus vectorsCELL GENESYS INC·Filed 2002·Granted Aug 2, 2005·8 cites·17 claims
- 1484US10155011B2Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleasesSANGAMO BIOSCIENCES INC·Filed 2015·Granted Dec 18, 2018·4 cites·13 claims
- 1584US9556438B2Gene vectorFOND CENTRO SAN RAFFAELE DEL MONTE TABOR·Filed 2014·Granted Jan 31, 2017·8 cites·20 claims
- 1682US8652837B2Method and means for producing high titer, safe, recombinant lentivirus vectorsNALDINI LUIGI·Filed 2007·Granted Feb 18, 2014·4 cites·21 claims
- 1782US7833789B2Monocyte cellSAN RAFFAELE CENTRO FOND·Filed 2007·Granted Nov 16, 2010·12 cites·10 claims
- 1882US2024218370A1Gene VectorOSPEDALE SAN RAFFAELE SRL·Filed 2023·Application pending·0 cites
- 1980US11407996B2Gene vectorOSPEDALE SAN RAFFAELE SRL·Filed 2019·Granted Aug 9, 2022·1 cites·17 claims
- 2079US10918668B2Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleasesSANGAMO THERAPEUTICS INC·Filed 2018·Granted Feb 16, 2021·1 cites·9 claims
- 2178US10117899B2Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cellsSANGAMO BIOSCIENCES INC·Filed 2014·Granted Nov 6, 2018·2 cites·11 claims
- 2278US9951328B2Gene vectorFOND TELETHON·Filed 2017·Granted Apr 24, 2018·2 cites·12 claims
- 2377US2023346844A1Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleasesSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2476US12485187B2Method for improving retroviral transduction and gene editing in hematopoietic stem cells using clyclosporin H and UM171OSPEDALE SAN RAFFAELE SRL·Filed 2024·Granted Dec 2, 2025·0 cites·22 claims
- 2575US9493827B2Determination of in vivo DNA double-strand break localization and application thereofVON KALLE CHRISTOF·Filed 2011·Granted Nov 15, 2016·5 cites·15 claims
- 2675US8501464B2Lentiviral vectors carrying synthetic bi-directional promoters and uses thereofNALDINI LUIGI·Filed 2004·Granted Aug 6, 2013·7 cites·16 claims
- 2774US2024342264A1Vector productionOSPEDALE SAN RAFFAELE S R I·Filed 2024·Application pending·0 cites
- 2870US11439666B2Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleasesSANGAMO THERAPEUTICS INC·Filed 2018·Granted Sep 13, 2022·0 cites·12 claims
- 2967US11957747B2Vector productionOSPEDALE SAN RAFFAELE SRL·Filed 2021·Granted Apr 16, 2024·0 cites·14 claims
- 3065US2025281540A1Methods for Haematopoietic Stem Cell TransplantationOSPEDALE SAN RAFFAELE SRL·Filed 2023·Application pending·0 cites
- 3163US11753643B2Gene vectorOSPEDALE SAN RAFFAELE SRL·Filed 2018·Granted Sep 12, 2023·0 cites·16 claims
- 3262US10287579B2Gene vectorBIFFI ALESSANDRA·Filed 2010·Granted May 14, 2019·1 cites·13 claims
- 3362US2025236870A1Permanent epigenetic gene silencingOSPEDALE SAN RAFFAELE SRL·Filed 2024·Application pending·0 cites
- 3461US2025376696A1Virus vector productionOSPEDALE SAN RAFFAELE SRL·Filed 2025·Application pending·0 cites
- 3558US12359217B2Virus vector productionOSPEDALE SAN RAFFAELE SRL·Filed 2019·Granted Jul 15, 2025·0 cites·18 claims
- 3658US11964027B2Method for improving retroviral transduction and gene editing in hematopoietic stem cells using cyclosporine h (CsH)OSPEDALE SAN RAFFAELE SRL·Filed 2018·Granted Apr 23, 2024·0 cites·17 claims
- 3757US2023174622A1Epidermal growth factor receptorOSPEDALE SAN RAFFAELE SRL·Filed 2021·Application pending·0 cites
- 3856US2025288617A1Gene TherapyOSPEDALE SAN RAFFAELE SRL·Filed 2023·Application pending·0 cites
- 3955US2023340471A1Permanent Epigenetic Gene SilencingOSPEDALE SAN RAFFAELE SRL·Filed 2022·Application pending·0 cites
- 4051US2020338131A1MethodOSPEDALE SAN RAFFAELE SRL·Filed 2020·Application pending·0 cites
- 4150US2021317411A1Compositions and methods for haematopoietic stem cell transplantationOSPEDALE SAN RAFFAELE SRL·Filed 2019·Application pending·0 cites
- 4250US2022273712A1Foxp3 engineered cd4+ t cells for use in treg-based immunotherapyUNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
- 4350US2024425851A1Polynucleotides useful for correcting mutations in the rag1 geneOSPEDALE SAN RAFFAELE S R L 50%·Filed 2022·Application pending·0 cites
- 4449US2025270587A1VectorOSPEDALE SAN RAFFAELE SRL·Filed 2021·Application pending·0 cites
- 4548US10617721B2Methods for genetic modification of stem cellsOSPEDALE SAN RAFFAELE SRL·Filed 2014·Granted Apr 14, 2020·0 cites·23 claims
- 4648US2021038744A1Use of lentiviral vectors expressing factor viiiBIOVERATIV THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4747US2022251161A1Agents and Methods for Treating Viral InfectionsOSPEDALE SAN RAFFAELE SRL·Filed 2020·Application pending·0 cites
- 4846US2020199626A1Use of lentiviral vectors expressing factor ixBIOVERATIV THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4945US12214055B2Systems and methods for treating hyper-igm syndromeEDITAS MEDICINE INC·Filed 2018·Granted Feb 4, 2025·0 cites·20 claims
- 5045US2022056484A1Selection by means of artificial transactivatorsOSPEDALE SAN RAFFAELE SRL·Filed 2019·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Luigi Naldini files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →